Efficacy and Safety of Azilsartan Compared to Olmesartan Medoxomil in Chinese Participants With Grade I or II Essential Hypertension

A phase 3 trial registered on ClinicalTrials.gov. The registry status is unknown. It plans to enroll 304 participants.

Also called NCT02407210

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; triple masking; primary purpose treatment
Phase
Phase 3
Enrolled
  • 304 participants (planned count) (from the registry)
Sponsor
Registry
  • NCT NCT02407210
Start date
(registry gives no type) (from the registry)
Primary completion
(anticipated) (from the registry)
Completion
Not reported
Countries
China (from the registry)
Registry status
  • Unknown status (from the registry)

Technical summary

Registry record NCT02407210. Randomized; triple masking; primary purpose treatment. Start 2015-01 (registry gives no type); primary completion 2015-10 (anticipated). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Efficacy and Safety of Azilsartan Compared to Olmesartan Medoxomil in Chinese Participants With Grade I or II Essential Hypertension
Condition
Essential Hypertension
Intervention (Drug)
azilsartan
Intervention (Drug)
Olmesartan medoxomil
Lead sponsor
Jiangsu HengRui Medicine Co., Ltd. (class: industry)

Record details

Record id
cardio:ct-nct02407210
Content hash
87bf86f3d7cd3fd6c8140fe10fe8e44e7e3992da322e5d1305cb9226a216e8e9